Jibin John, Sr. Manager, HCP Marketing – Dermatology, Regeneron
Jibin John has been part of the DUPIXENT team at Regeneron since 2019. Originally approved in 2017, DUPIXENT was considered a first-in-class drug for its indicated disease state. However, as competing agents began entering the market in 2022, Jibin and his team had to innovate and come up with new and unique ways to differentiate DUPIXENT and to fill existing educational gaps on DUPIXENT data to an HCP audience.
By taking the time to connect, listen, and work closely with HCPs, Jibin was able to identify what it was that HCPs were looking for in content and what types of programming would be most impactful and educational. Taking what he learned, Jibin was able to institute a new form of speaker programming with new and impactful content, which as a result saw an increase in audience participation by 7x that of previous program initiatives. Ultimately leading to the education of over 3,000 new HCPs on DUPIXENT over the course of three weeks.
Furthermore, Jibin’s commitment to his team, and the dermatology community, continues to be recognized by HCP providers and can be summed up with the following testimonial from the dermatology community. “Jibin is the glue that keeps HCPs connected to Regeneron and has an uncanny knack for always connecting the right people together. Jibin is highly intelligent, dedicated, motivated, and an absolutely wonderful human being. He understands the dermatology landscape in a way that few others do—and at such a young age, blazes a trail all his own.”
